Immunotherapy by cytotoxic T lympocytes stimulated by peptide
Show all
Papers (271):
Yuya Hirasawa, Yutaro Kubota, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, et al. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer research. 2024. 44. 8. 3397-3407
Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, et al. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Scientific reports. 2024. 14. 1. 11325-11325
Toshiaki Tsurui, Yuya Hirasawa, Yutaro Kubota, Kiyoshi Yoshimura, Takuya Tsunoda. Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report. World journal of gastrointestinal oncology. 2024. 16. 2. 557-562
Yutaro Kubota, Yusuke Aoki, Noriyuki Masaki, Koya Obara, Kazuyuki Hamada, Qinghong Han, Michael Bouvet, Takuya Tsunoda, Robert M Hoffman. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease. Biochemical and biophysical research communications. 2024. 695. 149418-149418
Koji Otsuka, Junya Isobe, Yoshiyuki Asai, Tomohisa Nakano, Kouya Hattori, Tomotake Ariyoshi, Takeshi Yamashita, Kentaro Motegi, Akira Saito, Masahiro Kohmoto, et al. Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer. Cancer immunology, immunotherapy : CII. 2024. 73. 2. 23-23
Nana Iriguchi, Atsushi Horiike, Tomoyuki Ishiguro, Ryotaro Ohkuma, Shigetoshi Nishihara, Satoshi Matsukuma, Hirotsugu Ariizumi, Reiko Yoshida, Yutaro Kubota, Ryosuke Hanaoka, et al. A case of primary lung cancer that led to the diagnosis of SMARCA4-deficient thoracic sarcoid tumor by oncogene panel testing. ANNALS OF ONCOLOGY. 2021. 32. S355-S355
Associations of polymorphisms in CCL4L1 with regorafenib-induced hand-foot skin reaction in colorectal cancer patients
(2023 the Japanese Society of Medical Oncology Annual Meeting. The 20th Anniversary Meeting 2023)
Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer
(第19回日本臨床腫瘍学会学術集会(JSMO2022) 2022)
Establishment for big data base of Microbiota closely related to diseases - Showa U bank -
(WCP2018 2018)
Professional career (2):
(BLANK)
(BLANK)
Work history (9):
2018 - 現在 昭和大学医学部内科学部門腫瘍内科学部門 主任教授・昭和大学病院腫瘍センター長
2016 - 昭和大学臨床薬理研究所臨床免疫腫瘍学講座 教授
2015 - メルクセローノ株式会社 MA Oncology部長
2010 - オンコセラピーサイエンス株式会社 代表取締役・社長
2006 - ワクチンサイエンス株式会社 代表取締役・社長
2005 - 東京大学医科学研究所付属病院 准教授
2000 - 東京大学医科学研究所付属病院外科 講師
1992 - 1995 City of Hope National Cancer Institute 留学 講師
1995 - Wakayama Medical University
Show all
Association Membership(s) (14):
日本がん免疫学会
, 日本臨床免疫腫瘍再生細胞療法研究会
, 日本Biotherapy学会
, 米国臨床腫瘍学会(ASCO)
, 欧州臨床腫瘍学会(ESMO)
, 米国癌学会(AACR)
, 米国がん免疫療法学会(SITC)
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, THE JAPAN LUNG CANCER SOCIETY
, 日本乳癌学会
, 日本癌治療学会
, 日本消化器外科学会
, 日本癌学会
, 日本外科学会